Tesamorelin vs CJC-1295
Both are stabilized GHRH analogs, so they share the core mechanism of amplifying GH release. They differ mainly in research emphasis: tesamorelin is closely tied to visceral-fat research, while CJC-1295 (no DAC) is the general-purpose pulse amplifier.
| Tesamorelin | CJC-1295 (no DAC) | |
|---|---|---|
| Compound class | Stabilized GHRH analog | GHRH analog (mod GRF 1-29) |
| Primary target | GHRH receptor | GHRH receptor |
| Category | Growth Hormone | Growth Hormone |
| Administration | Subcutaneous, daily | Subcutaneous, 1-3x daily |
| Research focus | Visceral-fat & metabolic research | Amplified GH pulse amplitude |
Key differences
- Mechanism: both are GHRH-receptor analogs that increase GH output; tesamorelin is a stabilized form studied specifically for visceral adiposity.
- Research focus: tesamorelin features in metabolic/visceral-fat research; CJC-1295 is the broader GH-pulse tool often stacked with a GHRP.
- Profile: tesamorelin is the more specialized molecule; CJC-1295 (no DAC) is the flexible workhorse.
- Both are subcutaneous and dosed daily.
Which is right for your research?
Tesamorelin is the visceral-fat-focused GHRH analog; CJC-1295 (no DAC) is the general GH-pulse amplifier. Both raise GH through the same receptor.
Frequently asked questions
Are tesamorelin and CJC-1295 both GHRH analogs?
Yes. Both are stabilized GHRH analogs that amplify GH release; they differ mainly in their typical research emphasis.
What is tesamorelin most studied for?
Tesamorelin is closely associated with visceral-fat and metabolic research.
How are they administered?
Both are subcutaneous research compounds dosed daily.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.